Javascript must be enabled to continue!
Performance-based Institutional Research Funding in Flanders, Belgium
View through CrossRef
Research and innovation is one of Flanders’ priorities and over the last three decades its public funding has strongly increased. Universities are key actors in this strategy. They have a large autonomy and receive a substantial share of additional R&D expenditures as lump sum funding.The Flemish authorities use quantitative indicators to allocate these lump sums to the universities. The funding formulae take into account each institution’s size, its research performance and, if relevant, its valorization activities. Also significant is the realization of governmental priorities, such as mobility and diversity of the academic staff. This paper describes the development of the Flemish university funding model, analyses its weaknesses and its strengths, and compares it with nine national metrics-based research performance funding systems.Policy highlightsFlanders, like many other regions and nations, has adopted performance-based research funding systems (PRFSs) to improve and provide accountability for its science and innovation system. The Flemish PRFS criteria have evolved considerably over the last three decades, and due to competition between universities and a consensus model of political decision making, the funding formula is comparatively complex.Building on an historical background of lump sum payments to universities, supporting both education and research, special supplementary funds for blue-sky research (BOF) and for strategic applied research, innovation, and outreach activities (IOF) were introduced by the Flemish government in 1994 and 2004, respectively. The “three-legged stool” funding mechanism for research in Flanders is unique within Europe.The introduction of publication and citation metrics in 2003 changed the character of the Flemish PRFS considerably, previously focused on measures of a university’s size in terms of students, degrees granted, and previous funding. Humanities and social sciences (HSS) research metrics were considered only after first adoption of bibliometric methods traditionally deployed for assessment of the natural and life sciences, but this is not unique to Flanders. HSS research has been addressed in Flanders through the creation of a special database to supplement standard citation indexes, the VABB-SHW. This special resource is a strong point of the Flemish PRFS, and other nations should appreciate the value of increased coverage of the HSS literature.The PRFS in Flanders differs from that of nine European nations in several ways: analysis is undertaken annually, it includes a diversity and mobility measure (2006), and one of interdisciplinary will soon be added.Flanders, like other nations using PRFSs, has generally seen increased research output and intellectual property activities after its introduction; however, in some nations the increase began before a PRFS was implemented. In almost all cases, demonstrating a causal link between a PRFS and increased output is difficult since R&D investments and the number of researchers have also increased for a variety of reasons. This is a cautionary note in not over-interpreting the effects or effectiveness of a PRFS.Flanders now exhibits one of the highest levels among European nations of research funding allocations determined by a PRFS: 50% of BOF-funding and 75% of IOF-funding. By employing such a metrics-heavy scheme, Flanders is a good candidate for a detailed study of unintended consequences of a PRFS, at the national, institutional, and research group and individual researcher level. This remains a large gap in our understanding of the use of a PRFS.
Title: Performance-based Institutional Research Funding in Flanders, Belgium
Description:
Research and innovation is one of Flanders’ priorities and over the last three decades its public funding has strongly increased.
Universities are key actors in this strategy.
They have a large autonomy and receive a substantial share of additional R&D expenditures as lump sum funding.
The Flemish authorities use quantitative indicators to allocate these lump sums to the universities.
The funding formulae take into account each institution’s size, its research performance and, if relevant, its valorization activities.
Also significant is the realization of governmental priorities, such as mobility and diversity of the academic staff.
This paper describes the development of the Flemish university funding model, analyses its weaknesses and its strengths, and compares it with nine national metrics-based research performance funding systems.
Policy highlightsFlanders, like many other regions and nations, has adopted performance-based research funding systems (PRFSs) to improve and provide accountability for its science and innovation system.
The Flemish PRFS criteria have evolved considerably over the last three decades, and due to competition between universities and a consensus model of political decision making, the funding formula is comparatively complex.
Building on an historical background of lump sum payments to universities, supporting both education and research, special supplementary funds for blue-sky research (BOF) and for strategic applied research, innovation, and outreach activities (IOF) were introduced by the Flemish government in 1994 and 2004, respectively.
The “three-legged stool” funding mechanism for research in Flanders is unique within Europe.
The introduction of publication and citation metrics in 2003 changed the character of the Flemish PRFS considerably, previously focused on measures of a university’s size in terms of students, degrees granted, and previous funding.
Humanities and social sciences (HSS) research metrics were considered only after first adoption of bibliometric methods traditionally deployed for assessment of the natural and life sciences, but this is not unique to Flanders.
HSS research has been addressed in Flanders through the creation of a special database to supplement standard citation indexes, the VABB-SHW.
This special resource is a strong point of the Flemish PRFS, and other nations should appreciate the value of increased coverage of the HSS literature.
The PRFS in Flanders differs from that of nine European nations in several ways: analysis is undertaken annually, it includes a diversity and mobility measure (2006), and one of interdisciplinary will soon be added.
Flanders, like other nations using PRFSs, has generally seen increased research output and intellectual property activities after its introduction; however, in some nations the increase began before a PRFS was implemented.
In almost all cases, demonstrating a causal link between a PRFS and increased output is difficult since R&D investments and the number of researchers have also increased for a variety of reasons.
This is a cautionary note in not over-interpreting the effects or effectiveness of a PRFS.
Flanders now exhibits one of the highest levels among European nations of research funding allocations determined by a PRFS: 50% of BOF-funding and 75% of IOF-funding.
By employing such a metrics-heavy scheme, Flanders is a good candidate for a detailed study of unintended consequences of a PRFS, at the national, institutional, and research group and individual researcher level.
This remains a large gap in our understanding of the use of a PRFS.
Related Results
Outcomes of Transplant-Eligible Patients with Myelodysplastic Syndrome-Refractory Anemia with Excess Blasts Registered in a Prospective Observational Study: The JALSG-CS11-MDS-SCT
Outcomes of Transplant-Eligible Patients with Myelodysplastic Syndrome-Refractory Anemia with Excess Blasts Registered in a Prospective Observational Study: The JALSG-CS11-MDS-SCT
Abstract
Introduction: Allogeneic hematopoietic stem cell transplantation (allo-SCT) is the sole curative therapy for myelodysplastic syndromes (MDS). Several studie...
Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma
Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma
Background: Lytic bone lesions are one of the most common clinical characteristics of patients with multiple myeloma (MM) and identification of bone lesions help distinguish betwee...
Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia
Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia
BACKGROUND
Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma in which bone marrow is infiltrated by immunoglobulin M (IgM)-producing clonal lymphopl...
Randomized Study of Digital Life Coaching during Autologous Stem Cell Transplantation
Randomized Study of Digital Life Coaching during Autologous Stem Cell Transplantation
Abstract
BACKGROUND: Autologous stem cell transplantation (ASCT) for multiple myeloma (MM) entails sudden life changes including acute symptom burden, changes in phy...
Trial in Progress: Phase I Open-Label Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma
Trial in Progress: Phase I Open-Label Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma
Abstract
Background:
GLUT4 inhibition is an attractive therapeutic option in multiple myeloma (MM) given the dependence of MM cells on glucose transpo...
Hematologic Improvement with Iron Chelation using therapy Deferasirox in Patients with Aplastic Anemia: A Subgroup Analysis of KAMS0112 Prospective Study,
Hematologic Improvement with Iron Chelation using therapy Deferasirox in Patients with Aplastic Anemia: A Subgroup Analysis of KAMS0112 Prospective Study,
Abstract
Abstract 3424
Patients with aplastic anemia (AA) are suffered from various complications related to bone marrow failure and peripheral cytope...
Combining the Number of Infectious Episodes and Interval of Chemotherapy to Transplantation May Predict a Transplant Outcome in Patients with Acute Myeloid Leukemia: A Retrospective Analysis of JALSG AML201 Study
Combining the Number of Infectious Episodes and Interval of Chemotherapy to Transplantation May Predict a Transplant Outcome in Patients with Acute Myeloid Leukemia: A Retrospective Analysis of JALSG AML201 Study
Abstract
Background
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapy for acute myeloid leukemia (AML),...
Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3-ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations
Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3-ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations
Genetic mutations in FLT3 (fms-like tyrosine kinase-3) play an important role in the pathogenesis of acute myeloid leukemia (AML). FLT3 internal tandem duplications (FLT3-ITD) occu...

